Adjuvant Bisphosphonates in Patients with Breast Cancer: Does the Potency Matter?

References

• Clézardin P . Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities. Bone Key Rep.2, 267 (2013).
   PubMedGoogle Scholar
• Weilbaecher KN , GuiseTA, MccauleyLK. Cancer to bone: a fatal attraction. Nat. Rev. Cancer11(6), 411–425 (2011).
   PubMed Web of Science ®Google Scholar
• Gnant M , ClézardinP. Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treat. Rev.38(5), 407–415 (2012).
   PubMed Web of Science ®Google Scholar
• Ben-Aharon I , VidalL, RizelSet al. Bisphosphonates in the adjuvant setting of breast cancer therapy – effect on survival: a systematic review and meta-analysis. PLoS ONE8(8), e70044 (2013).
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative G . Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet doi: 10.1016/S0140-6736(15)60908-4 (2015) ( Epub ahead of print).
   Google Scholar
• Rosen LS , GordonD, KaminskiMet al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer98(8), 1735–1744 (2003).
   PubMed Web of Science ®Google Scholar
• Coleman RE , WinterMC, CameronDet al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: Exploratory evidence for direct anti-tumour activity in breast cancer. Br. J. Cancer102(7), 1099–1105 (2010).
   PubMed Web of Science ®Google Scholar
• Saarto T , VehmanenL, VirkkunenP, BlomqvistC. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol.43(7), 650–656 (2004).
   PubMed Web of Science ®Google Scholar
• Powles T , PatersonA, MccloskeyEet al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res.8(2), R13 (2006).
   PubMed Web of Science ®Google Scholar
• Diel IJ , JaschkeA, SolomayerEFet al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann. Oncol.19(12), 2007–2011 (2008).
   PubMed Web of Science ®Google Scholar
• Paterson AH , AndersonSJ, LemberskyBCet al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project Protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol.13(7), 734–742 (2012).
   PubMed Web of Science ®Google Scholar
• Delmas PD , BalenaR, ConfravreuxE, HardouinC, HardyP, BremondA. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J. Clin. Oncol.15(3), 955–962 (1997).
   PubMed Web of Science ®Google Scholar
• Kristensen B , EjlertsenB, MouridsenHTet al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol.47(4), 740–746 (2008).
   PubMed Web of Science ®Google Scholar
• Leal T , TevaarwerkA, LoveRet al. Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer. Clin. Breast Cancer10(6), 471–476 (2010).
   PubMed Web of Science ®Google Scholar
• Gnant M , MlineritschB, StoegerHet al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann. Oncol.26(2), 313–320 (2015).
   PubMed Web of Science ®Google Scholar
• Brufsky AM , HarkerWG, BeckJTet al. Final 5 year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer118(5), 1192–1201 (2012).
   PubMed Web of Science ®Google Scholar
• Von Minckwitz G , MobusV, SchneeweissAet al. German adjuvant intergroup node-positive study: a Phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J. Clin. Oncol.31(28), 3531–3539 (2013).
   PubMed Web of Science ®Google Scholar
• Coleman R , De BoerR, EidtmannHet al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann. Oncol.24(2), 398–405 (2013).
   PubMed Web of Science ®Google Scholar
• Coleman R , CameronD, DodwellDet al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label Phase 3 trial. Lancet Oncol.15(9), 997–1006 (2014).
   PubMed Web of Science ®Google Scholar
• Kremer R , GagnonB, MeguerditchianAN, NadeauL, MayoN. Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study. J. Natl Cancer Inst.106(11), (2014).
   PubMedGoogle Scholar
• Friedman CF , DemicheleA, SuHIet al. Vitamin D deficiency in postmenopausal breast cancer survivors. J. Womens Health (Larchmt)21(4), 456–462 (2012).
   PubMed Web of Science ®Google Scholar
• Soki FN , ParkSI, MccauleyLK. The multifaceted actions of PTHrp in skeletal metastasis. Future Oncol.8(7), 803–817 (2012).
   PubMed Web of Science ®Google Scholar
• Marie PJ . Role of N-cadherin in bone formation. J. Cell Physiol.190(3), 297–305 (2002).
   PubMed Web of Science ®Google Scholar
• Huber BC , GrabmaierU, BrunnerS. Impact of parathyroid hormone on bone marrow-derived stem cell mobilization and migration. World J. Stem Cells6(5), 637–643 (2014).
   PubMedGoogle Scholar
• Berruti A , CookR, SaadFet al. Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration. Oncologist17(5), 645–652 (2012).
   PubMed Web of Science ®Google Scholar
• Winter MC , HolenI, ColemanRE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat. Rev.34(5), 453–475 (2008).
   PubMed Web of Science ®Google Scholar